Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT01442155
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 177
- Registration Number
- NCT01438749
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
Phase 2
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PlaceboDrug: RO4917523 1.5 mgDrug: RO4917523 0.5 mg
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 319
- Registration Number
- NCT01437657
A Study of RG1662 in Individuals With Down Syndrome
Phase 1
Completed
- Conditions
- Down Syndrome
- Interventions
- Drug: PlaceboDrug: RG1662
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01436955
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO4917838
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01433575
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: ribavirin [Copegus]
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1013
- Registration Number
- NCT01429792
- Locations
- 🇮🇱
Holy Family Medical Center; Gastroenterology, Nazareth, Israel
🇮🇱Chaim Sheba Medical Center; Gastroenterology, Ramat Gan, Israel
🇮🇱Maccabi Health Services MC, Tel Aviv, Israel
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Completed
- Conditions
- Anemia, Kidney Disease, Chronic
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT01422824
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: Trastuzumab emtansineDrug: Treatment of physician's choice
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 602
- Registration Number
- NCT01419197
A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01418274
A Study of RO5285119 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5285119Drug: placebo
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT01418963
© Copyright 2025. All Rights Reserved by MedPath